Electra Therapeutics, an inflammation-focused biotech, raised $350 million in its initial public offering on Nasdaq. Both Fierce Biotech and BioPharma Dive report the same figure, and both note the offering was upsized, meaning Electra sold more shares or priced above its original range.
The listing is part of a broader surge in biotech IPOs. BioPharma Dive adds that nearly a dozen biotech companies have matched or exceeded $300 million in their 2026 IPOs, a level of large new stock sales not seen since 2021. Fierce Biotech similarly describes Electra as the latest biotech to overshoot its own IPO expectations this year.
While the two sources agree on the core facts, BioPharma Dive provides the wider market context, whereas Fierce Biotech focuses more on Electra's individual positioning. Neither source specifies what Electra plans to do with the proceeds beyond general corporate purposes.